Y.D. More Investments Ltd Sells 318,077 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Y.D. More Investments Ltd decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 18.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,395,768 shares of the biotechnology company’s stock after selling 318,077 shares during the period. Y.D. More Investments Ltd owned about 0.20% of OPKO Health worth $2,059,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Rubric Capital Management LP boosted its position in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Barclays PLC raised its stake in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after buying an additional 876,272 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of OPKO Health in the second quarter valued at $592,000. Finally, BNP Paribas Financial Markets increased its holdings in OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were bought at an average cost of $1.62 per share, with a total value of $162,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This trade represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders bought 2,001,792 shares of company stock valued at $3,054,984. Insiders own 47.26% of the company’s stock.

OPKO Health Stock Up 4.0 %

Shares of OPK opened at $1.56 on Wednesday. The company’s 50-day moving average is $1.52 and its 200-day moving average is $1.52. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $173.60 million for the quarter, compared to analysts’ expectations of $181.32 million. During the same period in the prior year, the firm earned ($0.11) EPS. As a group, equities research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.